Anti-alpha-V integrin antibody for the treatment of prostate cancer

US9555110B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Axel Hoffmann · Berlin, DE
• Heinrich Lannert · Schwetzingen, DE
• Klaus Brischwein · Munich, DE
• Frederic Christian Pipp · Zöblitz, DE
• Juergen Reindl · Roßdorf, DE
• Karin Groll · Heilbad Heiligenstadt, DE
• Michael Zuehlsdorf · Darmstadt, DE
• Otmar Pfaff · Frankfurt am Main, DE
• Sabine Raab · Rosbach, DE
• Ulrike Dau · Darmstadt, DE
• Benoit Destenaves · Mayenne, FR

Key dates

• Filing date: Feb 7, 2012
• Grant date: Jan 31, 2017
• Expiry date: Aug 26, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/90
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.